GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
GSK Gets Positive Results in Blood-Cancer Drug Trial
Blenrep, in combination with other drugs, reduced the risk of death by 42% in patients with multiple myeloma whose first ...
GSK falls Wednesday, underperforms market
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
MM&M2d
GSK highlights positive Blenrep data from Phase 3 trial at ASH
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
FiercePharma2d
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
GSK rises Monday, outperforms market
GSK PLC GSK shares rose 2.90% to £13.83 Monday, on what proved to be an all-around great trading session for the stock market ...
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...
STAT2d
GSK myeloma medicine improves survival in trial, another step in the drug’s revival
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.